Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 3
2011 3
2012 2
2013 3
2014 3
2015 3
2016 2
2017 4
2019 2
2020 2
2021 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Chronic Kidney Disease--Chronic Liver Disease. An Immunologic Cross-talk.
Gluhovschi G, Petrică L, Sporea I, Timar R, Curescu M, Velciov S, Gluhovschi C. Gluhovschi G, et al. Among authors: curescu m. Rom J Intern Med. 2015 Jan-Mar;53(1):3-12. doi: 10.1515/rjim-2015-0001. Rom J Intern Med. 2015. PMID: 26076555 Free article. Review.
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Anastasiou OE, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Heidrich B, Mederacke I, von der Leyen H, Kahlhöfer J, von Karpowitz M, Hardtke S, Cornberg M, Yurdaydin C, Wedemeyer H. Anastasiou OE, et al. Among authors: curescu mg. Liver Int. 2024 Jan;44(1):139-147. doi: 10.1111/liv.15745. Epub 2023 Oct 3. Liver Int. 2024. PMID: 37787009
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Dinkelborg K, Kahlhöfer J, Dörge P, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, Wedemeyer H, Deterding K; HIDIT-2 Study Team. Dinkelborg K, et al. Among authors: curescu mg. Liver Int. 2023 Aug;43(8):1663-1676. doi: 10.1111/liv.15602. Epub 2023 May 15. Liver Int. 2023. PMID: 37183524 Clinical Trial.
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
Anastasiou OE, Yurdaydin C, Maasoumy B, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Liebig S, Bantel H, Bremer B, Manns MP, Cornberg M, Wedemeyer H. Anastasiou OE, et al. Among authors: curescu mg. J Viral Hepat. 2021 Feb;28(2):410-419. doi: 10.1111/jvh.13439. Epub 2020 Dec 12. J Viral Hepat. 2021. PMID: 33185325 Clinical Trial.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H. Bremer B, et al. Among authors: curescu mg. Liver Int. 2021 Feb;41(2):295-299. doi: 10.1111/liv.14740. Epub 2020 Dec 5. Liver Int. 2021. PMID: 33217778
Hepatitis Delta Virus Infection in Romania: Prevalence and Risk Factors.
Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Trifan A, Grigorescu M, Motoc A, Suceveanu A, Curescu M, Caruntu F, Sporea I, Brisc C, Rogoveanu I, Cerban R, Tugui L, Alexandrescu A. Gheorghe L, et al. Among authors: curescu m. J Gastrointestin Liver Dis. 2015 Dec;24(4):413-21. doi: 10.15403/jgld.2014.1121.244.dtv. J Gastrointestin Liver Dis. 2015. PMID: 26697566 Free article.
Elements of renal injury in patients with erysipelas.
Velciov S, Gluhovschi G, Feier V, Curescu M, Trandafirescu V, Petrică L, Gluhovschi C, Bob F, Bozdog G, Gadalean F, Florescu C, Bobu M, Chiliban A. Velciov S, et al. Among authors: curescu m. Rom J Intern Med. 2010;48(2):179-85. Rom J Intern Med. 2010. PMID: 21428183 Clinical Trial.
Anti-HDV IgM as a marker of disease activity in hepatitis delta.
Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Wranke A, et al. Among authors: curescu mg. PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014. PLoS One. 2014. PMID: 25072849 Free PMC article.
29 results